[go: up one dir, main page]

WO2018108130A1 - Process for preparation of novel androgen receptor antagonist - Google Patents

Process for preparation of novel androgen receptor antagonist Download PDF

Info

Publication number
WO2018108130A1
WO2018108130A1 PCT/CN2017/116226 CN2017116226W WO2018108130A1 WO 2018108130 A1 WO2018108130 A1 WO 2018108130A1 CN 2017116226 W CN2017116226 W CN 2017116226W WO 2018108130 A1 WO2018108130 A1 WO 2018108130A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
reaction
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/116226
Other languages
French (fr)
Inventor
Tingting Pan
Chunguang Xia
Yulei Yang
Aiming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Lianyungang Runzhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Pharmaceutical Industry, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Shanghai Institute of Pharmaceutical Industry
Publication of WO2018108130A1 publication Critical patent/WO2018108130A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to the field of pharmaceutical synthesis, in particular to an improved process for the preparation of a novel androgen receptor antagonist, specifically ODM-201 and its key intermediates.
  • Androgen receptor is a member of the nuclear receptor superfamily.
  • the superfamily has several members, but there are only 5 existing in vertebrates, which are progesterone receptors, estrogen receptors, androgen receptors (AR) , glucocorticoid receptors and mineralocorticoid receptors.
  • AR contains 918 amino acid residues, which constitutes three important domains, namely DNA binding domain (DBD) , ligand binding domain (LBD) , N-terminal domain (NTD) .
  • AR exists in cytoplasm and is combined with heat shock proteins (Hsp90) .
  • Hsp90 heat shock proteins
  • AR will release Hsp90, and combine with androgen in LBD zone at the same time. This combination will induce the structural transformation in the LBD zone, coupled with phosphorylation of receptors, and then activate AR.
  • the AR-androgen complex formed after activation will further initiate related genetic transcription and then exert its subsequent biological effect.
  • AR antagonists can inhibit the proliferation of prostatic cells and promote their apoptosis.
  • the patients in the early stages of prostate cancer will show the decreasing in the level of prostate specific antigen after treatment of AR antagonist, which accompanies reduction in prostate volume and symptoms in different degree, extension of survival. So far, there are 4 AR antagonists in the market, all belong to non-steroidal small molecule drug. Therefore, it is necessary to develop new non-steroidal AR antagonists for the treatment of prostatic cancer.
  • ODM-201 is a new type of androgen receptor antagonist, co-developed by Bayer AG and Orion Corp.
  • ODM-201 is structurally distinct from any known antiandrogens. Unlike other anti-androgen drugs, ODM-201 does not enter into the brain in a nonclinical model and can inhibit androgen receptor by blocking the nuclear ectopia. Phase I and Phase II clinical studies have shown ODM-201 has significant anti-tumor activity and good tolerance and safety. Its structure is as follow:
  • ODM-201 N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- (1-hydroxyethyl) -1H-pyrazole-3-carboxamide.
  • the carbon at position 1 of hydroxyethyl on the pyrazole ring has two configurations.
  • ODM-201 is a mixture of two diastereomers, namely the compounds of formula Ia and formula Ib as shown below.
  • the chemical name of the compound of formula Ia is N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- ( (R) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide
  • the compound of formula Ib is N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- ( (S) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide.
  • both the compounds of formula Ia and formula Ib are potent androgen receptor antagonists that could be used for the treatment of prostatic cancer.
  • ODM-201 could be synthesized by the method described in WO2011051540 as in route 1.
  • Route 1 the synthetic route of ODM-201.
  • compound 7 can be prepared according to the method disclosed in WO2012139930: compound 9 is cyclized with compound 10 under the catalysis of indium trichloride to form pyrazole compound 11; and compound 11 is hydrolyzed to give compound 7.
  • the drawbacks of synthetic route 1 are: (1) .
  • the starting material but-3-yn-2-one (compound 10) for synthesis of compound 7 is not commercially available in large quantities, and a small amount of customization of this compound is expensive which is not suitable for industrial production.
  • the preparation of compound 11 requires the use of indium trichloride as a catalyst. Indium trichloride is a transition metal. The post-treatment wastewater seriously pollutes the environment when indium trichloride is used in the industrial production.
  • Compound 11 is selectively reduced under the catalysis of ketoreductase (KRED enzyme) to give compound 12a; the hydroxyl group of compound 12a is protected by tert-butyldiphenylsilyl group to give compound 13a; compound 13a is hydrolyzed to give compound 14a; compound 14a undergoes an amidation reaction with compound 6 to give compound 15a; compound 15a is deprotected to give the compound of formula Ia.
  • compound 12a can also be prepared from compound 9 and compound 16a under the action of a catalyst.
  • Compound 11 is selectively reduced under the catalysis of ketoreductase (KRED enzyme) to give compound 12b; the hydroxyl group of compound 12b is protected by tert-butyldiphenylsilyl group to give compound 13b; compound 13b is hydrolyzed to give compound 14b; compound 14b undergoes an amidation reaction with compound 6 to give compound 15b; compound 15b is deprotected to give the compound of formula Ib.
  • compound 12b can also be prepared from compound 9 and compound 16b under the action of a catalyst.
  • the drawbacks of synthetic routes 2 and 3 are: (1) The preparation of starting material, namely compound 11 is difficult; (2) KRED enzyme is not suitable for industrial production as a biological enzyme; (3) Synthesis yield of compound 12a or compound 12b from compound 9 and compound 16a or compound 16b is very low, only 0.026%.
  • the published synthetic routes of ODM-201, the compounds of formula Ia and formula Ib are not suitable for industrial production.
  • This invention aims to provide a new process for preparing ODM-201 and its optical isomers (the compounds of formula Ia and formula Ib) which is suitable for industrial production.
  • the present invention provides a process for the preparation of a compound of formula VI, comprising: the compound of formula VI is synthesized from a compound of formula V through cyclization reaction.
  • R 1 is hydroxyl-protective group
  • R 2 is C 1-6 alkyl group.
  • the “hydroxyl-protective group” is selected from pivaloyl group, benzoyl group, acetyl group, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, triisopropylsilyl group, benzyl group, p-methoxybenzyl group, triphenylmethyl group, methoxymethyl group, 2-ethoxyethyl group, 2- (trimethylsilyl) ethoxymethyl group or allyl group, preferably t-butyldimethylsilyl group, t-butyldiphenylsilyl group, more preferably t-butyldimethylsilyl group.
  • R 2 is selected from methyl, ethyl, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group or t-butyl group.
  • R 2 is ethyl group.
  • the “cyclization reaction” is carried out in a solvent.
  • the “solvent” includes but is not limited to tetrachloromethane, chloroform, dichloromethane, n-hexane, n-heptane, n-octane, isooctane or mixtures of two or more thereof, preferably n-octane or isooctane, more preferably n-octane.
  • the cyclization reaction may be carried out at the reflux temperature of the reaction solvent, and may also be carried out at 100-200°C, specifically 120-130°C.
  • the invention provides a process for the preparation of a compound of formula V, comprising: (1) a compound of formula VII is synthesized from condensation reaction of a compound of formula VIII and a compound of formula IX; and (2) the compound of formula V is synthesized from dehydration reaction of the compound of formula VII.
  • R 1 and R 2 are as defined above.
  • the “condensation reaction” in step (1) is carried out in the presence of a base and a solvent.
  • the base used in step (1) includes but is not limited to potassium hydride, sodium hydride, n-butyllithium, t-butyllithium, isopropyllithium, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, sodium bis (trimethylsilyl) amide, or mixtures of two or more thereof, preferably lithium diisopropylamide or lithium bis (trimethylsilyl) amide, more preferably lithium bis (trimethylsilyl) amide.
  • the solvent used in step (1) includes but is not limited to acetonitrile, methyl tertiary butyl ether, isopropyl ether, dioxane, toluene, tetrahydrofuran, methyltetrahydrofuran, ethylene glycol diethyl ether, or mixtures of two or more thereof, preferably tetrahydrofuran or methyltetrahydrofuran, more preferably tetrahydrofuran.
  • the molar ratio of the compound of formula VIII to the compound of formula IX to be used in step (1) is 1: 1-2, preferably 1: 1.2-1.8, more preferably 1: 1.5-1.6.
  • the molar ratio of the compound of formula VIII to the base to be used in step (1) is 1: 1-2, preferably 1: 1.2-1.6, more preferably 1: 1.4-1.6.
  • the condensation reaction of step (1) may be carried out at -70 to -90°C, preferably at -75 to -80°C.
  • the “dehydration reaction” in step (2) is carried out in the presence of a dehydrant, a base and a solvent.
  • the dehydrant used in step (2) includes but is not limited to phosphorus oxychloride, cyanuric chloride, phosphorus pentoxide, thionyl chloride, trifluoroacetic anhydride, trifluoromethanesulfonic anhydride, oxyalyl chloride, or mixtures of two or more thereof, preferably trifluoroacetic anhydride or phosphorus oxychloride, more preferably trifluoroacetic anhydride.
  • the base used in step (2) includes but is not limited to triethylamine, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethyl pyridine, or mixtures of two or more thereof, preferably triethylamine or N, N-diisopropylethylamine, more preferably triethylamine.
  • the solvent used in step (2) includes but is not limited to chloroform, dichloromethane, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or tetrahydrofuran, more preferably dichloromethane.
  • the molar ratio of the compound of formula VII to the dehydrant to be used in step (2) is 1: 1-3, preferably 1: 1.5-2.5, more preferably 1: 1.5-2.
  • the molar ratio of the compound of formula VII to the base to be used in step (2) is 1: 1-10, preferably 1: 1-8, more preferably 1: 2-6.
  • the dehydration reaction of step (2) may be carried out at 15-30°C, preferably 25-30°C.
  • the invention provides a process for the preparation of a compound of formula VIII, comprising: (1) a compound of formula XI is synthesized from hydroxyl-protection reaction of a compound of formula X; and (2) the compound of formula VIII is synthesized from reduction reaction of the compound of formula XI.
  • R 1 is as defined above.
  • the “hydroxyl-protection reaction” in step (1) is carried out in the presence of a protective agent of hydroxyl group, a base and a solvent.
  • the protective agent of hydroxyl group used in step (1) includes but is not limited to pivaloyl chloride, benzoyl chloride, acetyl chloride, trimethylsilyl chloride, triethylsilyl chloride, t-butyldimethylsilyl chloride, t-butyldiphenylsilyl chloride, triisopropylsilyl chloride, benzyl chloride, p-methoxybenzyl chloride, triphenylmethyl chloride, chloromethyl methyl ether, 2-chloroethyl ethyl ether, 2- (trimethylsilyl) ethoxymethyl chloride or allyl chloride, preferably t-butyldimethylsilyl chloride or t-butyldiphenylsilyl chloride, more
  • the base used in step (1) includes but is not limited to triethylamine, imidazole, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethylpyridine, or mixtures of two or more thereof, preferably triethylamine, imidazole or N, N-diisopropylethylamine, more preferably imidazole.
  • the solvent used in step (1) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or N, N-dimethylformamide, more preferably dichloromethane.
  • the molar ratio of the compound of formula X to the hydroxyl protective agent to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
  • the molar ratio of the compound of formula X to the base to be used in step (1) is 1: 1-10, preferably 1: 1-4, more preferably 1: 1.5-2.
  • the hydroxyl protection reaction of step (1) may be carried out at 15-30°C, preferably 25-30°C.
  • the “reduction reaction” in step (2) is carried out in the presence of a reductant and a solvent.
  • the reductant used in step (2) includes but is not limited to lithium diethoxyaluminium hydride, lithium triethoxyaluminium hydride, lithium aluminium hydride or diisobutyl aluminium hydride, preferably lithium aluminium hydride or diisobutyl aluminium hydride, more preferably diisobutyl aluminium hydride;
  • the solvent used in step (2) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or tetrahydrofuran, more preferably dichloromethane.
  • the molar ratio of the compound of formula XI to the reductant to be used in step (2) is 1: 1-3, preferably 1: 1-1.5, more preferably 1: 1-1.1.
  • the reduction reaction of step (2) is carried out at -90 to -70°C, preferably -80 to -75°C.
  • the invention provides a process for the preparation of a compound of III, comprising: the compound of formula III is synthesized from hydrolysis reaction of a compound of formula VI.
  • R 1 and R 2 are as defined above.
  • the “hydrolysis reaction” is carried out in the presence of a base and a solvent.
  • the base includes but is not limited to sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, or mixtures of two or more thereof, preferably sodium hydroxide or potassium hydroxide, more preferably sodium hydroxide.
  • the solvent includes but is not limited to ethanol, methanol, isopropanol, tetrahydrofuran, or mixtures of two or more thereof, preferably ethanol or tetrahydrofuran.
  • the molar ratio of the compound of formula VI to the base to be used in hydrolysis reaction is 1: 1-5, preferably 1: 1-3, more preferably 1: 1.5-2.
  • the hydrolysis reaction may be carried out at the reflux temperature of the reaction solvent, specifically 40-70°C, more specifically 40-50°C.
  • the invention provides a process for the preparation of a compound of formula III, comprising: the compound of formula III is synthesized from cyclization reaction of a compound of formula V, and then the resulting product is hydrolyzed sequentially without separation.
  • R 1 and R 2 are as defined above.
  • the “cyclization reaction” may be carried out in the presence of a solvent.
  • the solvent includes but is not limited to tetrachloromethane, chloroform, dichloromethane, n-hexane, n-heptane, n-octane, isooctane, or mixtures of two or more thereof, preferably n-octane or isooctane, more preferably n-octane.
  • the “cyclization reaction” may be carried out at the reflux temperature of the reaction solvent, specifically 100-200°C, more specifically 120-130°C.
  • the hydrolysis reaction is carried out after the cyclization reaction, which is to add the base and solvent directly to the system without separation of the products from the cyclization reaction.
  • the solvent used in the hydrolysis reaction is a mixed solvent, including original solvent from the cyclization reaction and the added solvent for the hydrolysis reaction.
  • Original solvent and added solvent can be the same or different.
  • the hydrolysis reaction requires further addition of a base and a solvent.
  • the base used in the hydrolysis reaction includes but is not limited to sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, or mixtures of two or more thereof, preferably sodium hydroxide or potassium hydroxide, more preferably sodium hydroxide.
  • the solvent includes but is not limited to ethanol, methanol, isopropanol, tetrahydrofuran, or mixtures of two or more thereof, preferably ethanol or tetrahydrofuran.
  • the molar ratio of the compound of formula VI to the base to be used in the hydrolysis reaction is 1: 1-5, preferably 1: 1-3, more preferably 1: 1.5-2.
  • the base is used as its aqueous solution preferably.
  • the hydrolysis reaction is carried out at the reflux temperature of the reaction solvent, specifically 40-70°C, more specifically 40-50°C.
  • the invention provides a process for the preparation of a compound of formula I, comprising: (1) the compound of formula II is synthesized from amidation reaction of a compound of formula III and a compound of formula IV; and (2) the compound of formula I is synthesized from deprotection reaction of the compound of formula II.
  • R 1 and R 2 are as defined above.
  • the “amidation reaction” in step (1) is carried out in the presence of an activator of carboxylic acid, a condensation agent, a base and a solvent.
  • the activator of carboxylic acid used in step (1) includes but is not limited to 4-dimethylaminopyridine (DMAP) , 1-hydroxy-7-azabenzotriazole (HOAT) or 1-hydroxybenzotriazole (HOBT) , preferably HOBT.
  • the condensation agent used in step (1) includes but is not limited to N, N'-dicyclohexylcarbodiimide (DCC) or 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) , preferably EDCI.
  • the base used in step (1) includes but is not limited to triethylamine, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethylaminopyridine, or mixtures of two or more thereof, preferably N, N-diisopropylethylamine or triethylamine, more preferably N, N-diisopropylethylamine.
  • the solvent used in step (1) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane, tetrahydrofuran, or mixtures of two or more thereof, more preferably dichloromethane.
  • the molar ratio of the compound of formula III to the compound of formula IV to be used in step (1) is 1: 0.5-2, preferably 1: 0.7-1.2, more preferably 1: 0.8-1.
  • the molar ratio of the compound of formula III to the activator to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
  • the molar ratio of the compound of formula III to the condensation agent to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
  • the molar ratio of the compound of formula III to the base to be used in step (1) is 1: 1-5, preferably 1: 1-2, more preferably 1: 1-1.2.
  • reaction of step (1) may be carried out at 15-30°C, preferably 25-30°C.
  • the “deprotection reaction” in step (2) is carried out in the presence of a deprotective agent and a solvent.
  • the deprotective agent includes but is not limited to hydrofluoric acid, 2-iodoxybenzoic acid, sodium periodate, zinc bromide, zirconium tetrachloride or tetrabutylammonium fluoride, preferably tetrabutylammonium fluoride or hydrofluoric acid, more preferably tetrabutylammonium fluoride.
  • the solvent includes but is not limited to acetonitrile, methyl tertiary butyl ether, isopropyl ether, dioxane, toluene, tetrahydrofuran, methyltetrahydrofuran, ethylene glycol diethyl ether, or mixtures of two or more thereof, preferably tetrahydrofuran or toluene, more preferably tetrahydrofuran.
  • the molar ratio of the compound of formula II to the deprotective agent in step (2) is 1: 1-5, preferably 1: 1-3, more preferably 1: 1-2.
  • the reaction in step (2) may be carried out at 15-30°C, preferably 25-30°C.
  • the compound with carbon atom marked with * means a mixture of R and S configurations at any ratio, a single enantiomer with R configuration at the carbon atom marked with *, or a single enantiomer with S configuration at the carbon atom marked with *.
  • any ratio means the ratio of R configuration to S configuration is, more than 1, equal to 1, less than 1, can be about 50: 50 to 40: 60, or 50: 50 to 60: 40 etc, preferably racemate.
  • configuration transformation rarely occurs at the marked *carbon atom.
  • the invention provides a process for the preparation of ODM-201, comprising: (1) a compound of formula (XI’) is synthesized from hydroxyl-protective reaction of a compound of formula (X’) ; (2) a compound of formula (VIII’) is synthesized from reduction reaction of the compound of formula (XI’) ; (3) a compound of formula (VII’) is synthesized from condensation reaction of the compounds of formula (VIII’) and formula IX; (4) a compound of formula (V’) is synthesized from dehydration reaction of the compound of formula (VII’) ; (5) a compound of formula (VI’) is synthesized from cyclization reaction of the compound of formula (V’) ; (6) a compound of formula (III’) is synthesized from hydrolysis reaction of the compound of formula (VI’) ; (7) a compound of formula (II’) is synthesized from amidation reaction of the compounds of formula (III’) and formula IV; (8) ODM-201 is synthesized from
  • R 1 and R 2 are as defined above.
  • R 1 is selected from t-butyldimethylsilyl group
  • R 2 is selected from ethyl group.
  • the compound of formula (VI’) from step (5) can be directly used in step (6) without separation.
  • the reaction condition is also as defined above.
  • the invention provides specific compounds as follow:
  • the invention also provides the use of above specific compounds in the preparation of ODM-201.
  • the invention provides a process for the preparation of the compound of formula Ia, comprising: (1) a compound of formula (XIa) is synthesized from hydroxyl-protective reaction of a compound of formula (Xa) ; (2) a compound of formula (VIIIa) is synthesized from reduction reaction of the compound of formula (XIa) ; (3) a compound of formula (VIIa) is synthesized from condensation reaction of the compounds of formula (VIIIa) and formula IX; (4) a compound of formula (Va) is synthesized from dehydration reaction of the compound of formula (VIIa) ; (5) a compound of formula (VIa) is synthesized from cyclization reaction of the compound of formula (Va) ; (6) a compound of formula (IIIa) is synthesized from hydrolysis reaction of the compound of formula (VIa) ; (7) a compound of formula (IIa) is synthesized from amidation reaction of the compounds of formula (IIIa) and formula IV; (8) the compound of formula
  • R 1 and R 2 are as defined above.
  • R 1 is selected from t-butyldimethylsilyl group; R 2 is ethyl group.
  • the compound of formula (VIa) from step (5) can be directly used in step (6) without separation.
  • the reaction condition is also as defined above.
  • the invention provides specific compounds as follow:
  • the invention provides a process of the preparation of a compound of formula Ib, comprising: (1) a compound of formula (XIb) is synthesized from hydroxyl-protective reaction of a compound of formula (Xb) ; (2) a compound of formula (VIIIb) is synthesized from reduction reaction of the compound of formula (XIb) ; (3) a compound of formula (VIIb) is synthesized from condensation reaction of the compounds of formula (VIIIb) and formula IX; (4) a compound of formula (Vb) is synthesized from dehydration reaction of the compound of formula (VIIb) ; (5) a compound of formula (VIb) is synthesized from cyclization reaction of the compound of formula (Vb) ; (6) compound of formula (IIIb) is synthesized from hydrolysis reaction of the compound of formula (VIb) ; (7) a compound of formula (IIb) is synthesized from amidation reaction of the compounds of formula (IIIb) and formula IV; (8) the compound of formula I
  • R 1 and R 2 are as defined above.
  • R 1 is selected from t-butyldimethylsilyl group; R 2 is ethyl group.
  • the compound of formula (VIb) from step (5) can be directly used in step (6) without separation.
  • the reaction condition is also as defined above.
  • the invention provides specific compounds as follow:
  • the said hydroxyl protective group in this invention includes but is not limited to the hydroxyl protective groups described in ⁇ Protective Groups in Organic Synthesis> (4 th edition, John Wiley &Sons: New Jersey) .
  • This literature is incorporated into this invention as reference.
  • a person having ordinary skill in the art could take well known methods to get connect with or rid of the compounds.
  • the hydroxyl protective group described in this invention is selected from pivaloyl group, benzoyl group, acetyl group, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, triisopropylsilyl group, benzyl group, p-methoxybenzyl group, triphenylmethyl group, methoxymethyl group, 2-ethoxyethyl group, 2- (trimethylsilyl) ethoxymethyl group and allyl group.
  • the compound of formula IV can be synthesized according the method published in CN201280019463.1
  • the compound of formula IX is commercially available or can be prepared according to methods known in the art.
  • TBSCl refers to t-butyldimethylsilyl chloride.
  • DIBAL-H diisobutylaluminium hydride
  • LIHMDS lithium bis (trimethylsilyl) amide
  • DIPEA N, N-diisopropylethylamine
  • HOBt refers to1-hydroxybenzotriazole.
  • EDCI refers to 1- (3-dimethylaminopropyl) -3-ethylcarbodiimidehydrochloride.
  • THF tetrahydrofuran
  • dehydrant refers to the reagent that could help dehydration under heating or catalyst.
  • condensation reaction refers to a reaction that one big molecule is formed by covalent bond after interaction between two or more organic molecules or intramolecular reaction within one molecule, and often accompanied by the lost of small molecular (such as water, hydrogen chloride and alcohol etc. ) .
  • activator of carboxylic acid refers to the reagent that reacts with carboxylic acid, removes one water molecule, and forms a new compound which could increase the reactivity of carboxylic group.
  • condensation agent refers to a reagent added in the condensation reaction.
  • a reagent capable of forming an active intermediate with a carbonyl-containing compound is a condensing agent, and the resulting active intermediate is further reacted with an amine to obtain an amide.
  • the term of “deprotective agent” refers to the reagent that can remove the hydroxyl protective agent, amino protective agent and the like under heating or catalyst.
  • the chiral compound is in enantiomeric excess.
  • enantiomeric excess is the content of a chiral isomer is equal or over about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%or about 99.99%.
  • compounds can have specific geometrical or steric isomers.
  • the invention assumes all these compounds, including cis-and trans-isomers, (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereoisomers, (D) -isomers, (L) -isomers and racemic mixtures or other mixtures thereof.
  • mixtures with stereomeric or diastereomeric excess are both belonging to the range of this invention.
  • Alkyl substituent and the like may contain other asymmetric carbon atoms. All these isomers or their mixtures are belonging to the range of this invention.
  • the reaction is optionally carried out in a solvent. All the solvents are commercially available and can be used without any further purification. Normally, the reaction is conducted under inert nitrogen and in anhydrous solvents.
  • the compounds are named by a person or software Commercially available compounds use the inventory from suppliers.
  • room temperature refers to 25-30°C.
  • reaction time unit of “h” refers to hour (s) .
  • This invention provides a preparation method of a compound of formula I, which has the advantages of easily obtainable starting material, high atomic utilization rate, mild reaction condition, easy post-treatment.
  • single isomers of formula Ia and formula Ib and ODM-201 can be synthesized directionally by controlling the stereochemistry of starting material, i.e., the compound of XI, with the advantages of simple and controllable process and suitability for industrial production.
  • Example 13 5- ( (S) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide
  • reaction mixture was poured onto a saturated aqueous solution of sodium potassium tartrate (300mL) and extracted with ether (300mL ⁇ 3) .
  • the combined organic layer was washed with water (three times) and brine (three times) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound. Yield 15.6 g (89.6%) .
  • Example 20 5- (-1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide
  • Example 21 N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- (1-hydroxyethyl) -1H-pyrazole-3-carboxamide (ODM-201)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of a novel androgen receptor antagonist is provided, comprising essentially conducting cyclization reaction of a compound of formula V to obtain a compound of formula VI. This method has the advantages of easily obtainable starting material, high atomic utilization rate, mild reaction conditions, and simply post-treatment. In addition, ODM-201 and its single isomers can be synthesized directionally by controlling the stereochemistry of starting material, with the advantages of simple and controllable process and suitability for industrial production.

Description

[Title established by the ISA under Rule 37.2] PROCESS FOR PREPARATION OF NOVEL ANDROGEN RECEPTOR ANTAGONIST TECHNICAL FIELD
The present invention relates to the field of pharmaceutical synthesis, in particular to an improved process for the preparation of a novel androgen receptor antagonist, specifically ODM-201 and its key intermediates.
BACKGROUND OF THE INVENTION
Androgen receptor (AR) is a member of the nuclear receptor superfamily. The superfamily has several members, but there are only 5 existing in vertebrates, which are progesterone receptors, estrogen receptors, androgen receptors (AR) , glucocorticoid receptors and mineralocorticoid receptors. AR contains 918 amino acid residues, which constitutes three important domains, namely DNA binding domain (DBD) , ligand binding domain (LBD) , N-terminal domain (NTD) .
Normally, AR exists in cytoplasm and is combined with heat shock proteins (Hsp90) . When androgen (testosterone or dihydrotestosterone) is present, AR will release Hsp90, and combine with androgen in LBD zone at the same time. This combination will induce the structural transformation in the LBD zone, coupled with phosphorylation of receptors, and then activate AR. The AR-androgen complex formed after activation will further initiate related genetic transcription and then exert its subsequent biological effect.
In vitro experiments show that AR antagonists can inhibit the proliferation of prostatic cells and promote their apoptosis. The patients in the early stages of prostate cancer will show the decreasing in the level of prostate specific antigen after treatment of AR antagonist, which accompanies reduction in prostate volume and symptoms in different degree, extension of survival. So far, there are 4 AR antagonists in the market, all belong to non-steroidal small molecule drug. Therefore, it is necessary to develop new non-steroidal AR antagonists for the treatment of prostatic cancer.
ODM-201 is a new type of androgen receptor antagonist, co-developed by Bayer AG and Orion Corp. ODM-201 is structurally distinct from any known antiandrogens. Unlike other anti-androgen drugs, ODM-201 does not enter into the brain in a nonclinical model and can inhibit androgen receptor by blocking the nuclear ectopia. Phase I and Phase II clinical studies have shown ODM-201 has significant anti-tumor activity and good tolerance and safety. Its  structure is as follow:
Figure PCTCN2017116226-appb-000001
The chemical name of ODM-201 is N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- (1-hydroxyethyl) -1H-pyrazole-3-carboxamide. The carbon at position 1 of hydroxyethyl on the pyrazole ring has two configurations. ODM-201 is a mixture of two diastereomers, namely the compounds of formula Ia and formula Ib as shown below. The chemical name of the compound of formula Ia is N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- ( (R) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide, while the compound of formula Ib is N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- ( (S) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide. According to the WO2016120530, both the compounds of formula Ia and formula Ib are potent androgen receptor antagonists that could be used for the treatment of prostatic cancer.
Figure PCTCN2017116226-appb-000002
ODM-201 could be synthesized by the method described in WO2011051540 as in route 1.
Route 1: the synthetic route of ODM-201.
Figure PCTCN2017116226-appb-000003
Compound 1 and compound 2 undergo carbon-carbon coupling reaction to obtain compound 3; compound 3 undergoes hydrolysis reaction to obtain compound 4; compound 4 undergoes a substitution reaction with compound 5 before the product is hydrolyzed to obtain compound 6; compound 6 and compound 7 are condensed into amide to obtain compound 8; and the carbonyl group of compound 8 is reduced to obtain ODM-201.
Among them, compound 7 can be prepared according to the method disclosed in WO2012139930: compound 9 is cyclized with compound 10 under the catalysis of indium trichloride to form pyrazole compound 11; and compound 11 is hydrolyzed to give compound 7.
The drawbacks of synthetic route 1 are: (1) . The starting material but-3-yn-2-one (compound 10) for synthesis of compound 7 is not commercially available in large quantities, and a small amount of customization of this compound is expensive which is not suitable for industrial production. (2) . The preparation of compound 11 requires the use of indium trichloride as a catalyst. Indium trichloride is a transition metal. The post-treatment wastewater seriously pollutes the environment when indium trichloride is used in the industrial production.
Two single diastereomers of ODM-201, namely the compounds of Formula Ia and Formula Ib, could be synthesized according to the method published in WO2016120530, as  showed in route 2 and route 3.
Route 2: the synthetic route of the compound of formula Ia
Figure PCTCN2017116226-appb-000004
Compound 11 is selectively reduced under the catalysis of ketoreductase (KRED enzyme) to give compound 12a; the hydroxyl group of compound 12a is protected by tert-butyldiphenylsilyl group to give compound 13a; compound 13a is hydrolyzed to give compound 14a; compound 14a undergoes an amidation reaction with compound 6 to give compound 15a; compound 15a is deprotected to give the compound of formula Ia. Among them, compound 12a can also be prepared from compound 9 and compound 16a under the action of a catalyst.
Route 3: the synthetic route of the compound of formula Ib
Figure PCTCN2017116226-appb-000005
Compound 11 is selectively reduced under the catalysis of ketoreductase (KRED enzyme) to give compound 12b; the hydroxyl group of compound 12b is protected by tert-butyldiphenylsilyl group to give compound 13b; compound 13b is hydrolyzed to give compound 14b; compound 14b undergoes an amidation reaction with compound 6 to give compound 15b; compound 15b is deprotected to give the compound of formula Ib. Among them, compound 12b can also be prepared from compound 9 and compound 16b under the action of a catalyst.
The drawbacks of synthetic routes 2 and 3 are: (1) The preparation of starting material, namely compound 11 is difficult; (2) KRED enzyme is not suitable for industrial production as a biological enzyme; (3) Synthesis yield of compound 12a or compound 12b from compound 9 and compound 16a or compound 16b is very low, only 0.026%.
The published synthetic routes of ODM-201, the compounds of formula Ia and formula Ib are not suitable for industrial production. This invention aims to provide a new process for preparing ODM-201 and its optical isomers (the compounds of formula Ia and formula Ib) which is suitable for industrial production.
SUMMARY OF THE INVENTION
In the first aspect, the present invention provides a process for the preparation of a compound of formula VI, comprising: the compound of formula VI is synthesized from a compound of formula V through cyclization reaction.
Figure PCTCN2017116226-appb-000006
Wherein, R1 is hydroxyl-protective group; R2 is C1-6 alkyl group.
In some representative embodiments, the “hydroxyl-protective group” is selected from pivaloyl group, benzoyl group, acetyl group, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, triisopropylsilyl group, benzyl group, p-methoxybenzyl group, triphenylmethyl group, methoxymethyl group, 2-ethoxyethyl group, 2- (trimethylsilyl) ethoxymethyl group or allyl group, preferably t-butyldimethylsilyl group, t-butyldiphenylsilyl group, more preferably t-butyldimethylsilyl group.
In some representative embodiments, R2 is selected from methyl, ethyl, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group or t-butyl group.
In some representative embodiments, R2 is ethyl group.
In some representative embodiments, the “cyclization reaction” is carried out in a solvent. The “solvent” includes but is not limited to tetrachloromethane, chloroform, dichloromethane, n-hexane, n-heptane, n-octane, isooctane or mixtures of two or more thereof, preferably n-octane or isooctane, more preferably n-octane.
In some representative embodiments, the cyclization reaction may be carried out at the reflux temperature of the reaction solvent, and may also be carried out at 100-200℃, specifically 120-130℃.
In the second aspect, the invention provides a process for the preparation of a compound of formula V, comprising: (1) a compound of formula VII is synthesized from condensation reaction of a compound of formula VIII and a compound of formula IX; and (2) the compound of formula V is synthesized from dehydration reaction of the compound of formula VII.
Figure PCTCN2017116226-appb-000007
Wherein, R1 and R2 are as defined above.
In some representative embodiments, the “condensation reaction” in step (1) is carried out in the presence of a base and a solvent. The base used in step (1) includes but is not limited to potassium hydride, sodium hydride, n-butyllithium, t-butyllithium, isopropyllithium, lithium diisopropylamide, lithium bis (trimethylsilyl) amide, sodium bis (trimethylsilyl) amide, or mixtures of two or more thereof, preferably lithium diisopropylamide or lithium bis (trimethylsilyl) amide, more preferably lithium bis (trimethylsilyl) amide. The solvent used in step (1) includes but is not limited to acetonitrile, methyl tertiary butyl ether, isopropyl ether, dioxane, toluene, tetrahydrofuran, methyltetrahydrofuran, ethylene glycol diethyl ether, or mixtures of two or more thereof, preferably tetrahydrofuran or methyltetrahydrofuran, more preferably tetrahydrofuran.
In some representative embodiments, the molar ratio of the compound of formula VIII to the compound of formula IX to be used in step (1) is 1: 1-2, preferably 1: 1.2-1.8, more preferably 1: 1.5-1.6.
In some representative embodiments, the molar ratio of the compound of formula VIII to the base to be used in step (1) is 1: 1-2, preferably 1: 1.2-1.6, more preferably 1: 1.4-1.6.
In some representative embodiments, the condensation reaction of step (1) may be carried out at -70 to -90℃, preferably at -75 to -80℃.
In some representative embodiments, the “dehydration reaction” in step (2) is carried out in the presence of a dehydrant, a base and a solvent. The dehydrant used in step (2) includes but is not limited to phosphorus oxychloride, cyanuric chloride, phosphorus pentoxide, thionyl chloride, trifluoroacetic anhydride, trifluoromethanesulfonic anhydride, oxyalyl chloride, or mixtures of two or more thereof, preferably trifluoroacetic anhydride or phosphorus oxychloride, more preferably trifluoroacetic anhydride. The base used in step (2) includes but is not limited to triethylamine, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethyl pyridine, or mixtures  of two or more thereof, preferably triethylamine or N, N-diisopropylethylamine, more preferably triethylamine. The solvent used in step (2) includes but is not limited to chloroform, dichloromethane, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or tetrahydrofuran, more preferably dichloromethane.
In some representative embodiments, the molar ratio of the compound of formula VII to the dehydrant to be used in step (2) is 1: 1-3, preferably 1: 1.5-2.5, more preferably 1: 1.5-2.
In some representative embodiments, the molar ratio of the compound of formula VII to the base to be used in step (2) is 1: 1-10, preferably 1: 1-8, more preferably 1: 2-6.
In some representative embodiments, the dehydration reaction of step (2) may be carried out at 15-30℃, preferably 25-30℃.
In the third aspect, the invention provides a process for the preparation of a compound of formula VIII, comprising: (1) a compound of formula XI is synthesized from hydroxyl-protection reaction of a compound of formula X; and (2) the compound of formula VIII is synthesized from reduction reaction of the compound of formula XI.
Figure PCTCN2017116226-appb-000008
Wherein, R1 is as defined above.
In some representative embodiments, the “hydroxyl-protection reaction” in step (1) is carried out in the presence of a protective agent of hydroxyl group, a base and a solvent. The protective agent of hydroxyl group used in step (1) includes but is not limited to pivaloyl chloride, benzoyl chloride, acetyl chloride, trimethylsilyl chloride, triethylsilyl chloride, t-butyldimethylsilyl chloride, t-butyldiphenylsilyl chloride, triisopropylsilyl chloride, benzyl chloride, p-methoxybenzyl chloride, triphenylmethyl chloride, chloromethyl methyl ether, 2-chloroethyl ethyl ether, 2- (trimethylsilyl) ethoxymethyl chloride or allyl chloride, preferably t-butyldimethylsilyl chloride or t-butyldiphenylsilyl chloride, more preferably t-butyldimethylsilyl chloride. The base used in step (1) includes but is not limited to triethylamine, imidazole, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethylpyridine, or mixtures of two or more thereof, preferably triethylamine, imidazole or N, N-diisopropylethylamine, more preferably  imidazole. The solvent used in step (1) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or N, N-dimethylformamide, more preferably dichloromethane.
In some representative embodiments, the molar ratio of the compound of formula X to the hydroxyl protective agent to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
In some representative embodiments, the molar ratio of the compound of formula X to the base to be used in step (1) is 1: 1-10, preferably 1: 1-4, more preferably 1: 1.5-2.
In some representative embodiments, the hydroxyl protection reaction of step (1) may be carried out at 15-30℃, preferably 25-30℃.
In some representative embodiments, the “reduction reaction” in step (2) is carried out in the presence of a reductant and a solvent. The reductant used in step (2) includes but is not limited to lithium diethoxyaluminium hydride, lithium triethoxyaluminium hydride, lithium aluminium hydride or diisobutyl aluminium hydride, preferably lithium aluminium hydride or diisobutyl aluminium hydride, more preferably diisobutyl aluminium hydride; the solvent used in step (2) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane or tetrahydrofuran, more preferably dichloromethane.
In some representative embodiments, the molar ratio of the compound of formula XI to the reductant to be used in step (2) is 1: 1-3, preferably 1: 1-1.5, more preferably 1: 1-1.1.
In some representative embodiments, the reduction reaction of step (2) is carried out at -90 to -70℃, preferably -80 to -75℃.
In the fourth aspect, the invention provides a process for the preparation of a compound of III, comprising: the compound of formula III is synthesized from hydrolysis reaction of a compound of formula VI.
Figure PCTCN2017116226-appb-000009
Wherein, R1 and R2 are as defined above.
In some representative embodiments, the “hydrolysis reaction” is carried out in the presence of a base and a solvent. The base includes but is not limited to sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, or mixtures of two or more thereof, preferably sodium hydroxide or potassium hydroxide, more preferably sodium hydroxide. The solvent includes but is not limited to ethanol, methanol, isopropanol, tetrahydrofuran, or mixtures of two or more thereof, preferably ethanol or tetrahydrofuran.
In some representative embodiments, the molar ratio of the compound of formula VI to the base to be used in hydrolysis reaction is 1: 1-5, preferably 1: 1-3, more preferably 1: 1.5-2.
In some representative embodiments, the hydrolysis reaction may be carried out at the reflux temperature of the reaction solvent, specifically 40-70℃, more specifically 40-50℃.
In the fifth aspect, the invention provides a process for the preparation of a compound of formula III, comprising: the compound of formula III is synthesized from cyclization reaction of a compound of formula V, and then the resulting product is hydrolyzed sequentially without separation.
Figure PCTCN2017116226-appb-000010
Wherein, R1 and R2 are as defined above.
In some representative embodiments, the “cyclization reaction” may be carried out in the presence of a solvent. The solvent includes but is not limited to tetrachloromethane, chloroform, dichloromethane, n-hexane, n-heptane, n-octane, isooctane, or mixtures of two or more thereof, preferably n-octane or isooctane, more preferably n-octane.
In some representative embodiments, the “cyclization reaction” may be carried out at the reflux temperature of the reaction solvent, specifically 100-200℃, more specifically 120-130℃.
In some representative embodiments, the hydrolysis reaction is carried out after the cyclization reaction, which is to add the base and solvent directly to the system without separation of the products from the cyclization reaction. More specifically, the solvent used in  the hydrolysis reaction is a mixed solvent, including original solvent from the cyclization reaction and the added solvent for the hydrolysis reaction. Original solvent and added solvent can be the same or different.
In some representative embodiments, the hydrolysis reaction requires further addition of a base and a solvent. The base used in the hydrolysis reaction includes but is not limited to sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, cesium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, or mixtures of two or more thereof, preferably sodium hydroxide or potassium hydroxide, more preferably sodium hydroxide.; The solvent includes but is not limited to ethanol, methanol, isopropanol, tetrahydrofuran, or mixtures of two or more thereof, preferably ethanol or tetrahydrofuran.
In some representative embodiments, the molar ratio of the compound of formula VI to the base to be used in the hydrolysis reaction is 1: 1-5, preferably 1: 1-3, more preferably 1: 1.5-2. The base is used as its aqueous solution preferably.
In some representative embodiments, the hydrolysis reaction is carried out at the reflux temperature of the reaction solvent, specifically 40-70℃, more specifically 40-50℃.
In the sixth aspect, the invention provides a process for the preparation of a compound of formula I, comprising: (1) the compound of formula II is synthesized from amidation reaction of a compound of formula III and a compound of formula IV; and (2) the compound of formula I is synthesized from deprotection reaction of the compound of formula II.
Figure PCTCN2017116226-appb-000011
Wherein, R1 and R2 are as defined above.
In some representative embodiments, the “amidation reaction” in step (1) is carried out  in the presence of an activator of carboxylic acid, a condensation agent, a base and a solvent. The activator of carboxylic acid used in step (1) includes but is not limited to 4-dimethylaminopyridine (DMAP) , 1-hydroxy-7-azabenzotriazole (HOAT) or 1-hydroxybenzotriazole (HOBT) , preferably HOBT. The condensation agent used in step (1) includes but is not limited to N, N'-dicyclohexylcarbodiimide (DCC) or 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) , preferably EDCI. The base used in step (1) includes but is not limited to triethylamine, N, N-diisopropylethylamine, pyridine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, tetramethyl guanidine, 4-dimethylaminopyridine, or mixtures of two or more thereof, preferably N, N-diisopropylethylamine or triethylamine, more preferably N, N-diisopropylethylamine. The solvent used in step (1) includes but is not limited to chloroform, dichloromethane, N, N-dimethylformamide, tetrahydrofuran, 1, 2-dichloroethane, acetonitrile, or mixtures of two or more thereof, preferably dichloromethane, tetrahydrofuran, or mixtures of two or more thereof, more preferably dichloromethane.
In some representative embodiments, the molar ratio of the compound of formula III to the compound of formula IV to be used in step (1) is 1: 0.5-2, preferably 1: 0.7-1.2, more preferably 1: 0.8-1.
In some representative embodiments, the molar ratio of the compound of formula III to the activator to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
In some representative embodiments, the molar ratio of the compound of formula III to the condensation agent to be used in step (1) is 1: 1-2, preferably 1: 1-1.5, more preferably 1: 1-1.2.
In some representative embodiments, the molar ratio of the compound of formula III to the base to be used in step (1) is 1: 1-5, preferably 1: 1-2, more preferably 1: 1-1.2.
In some representative embodiments, the reaction of step (1) may be carried out at 15-30℃, preferably 25-30℃.
In some representative embodiments, the “deprotection reaction” in step (2) is carried out in the presence of a deprotective agent and a solvent. The deprotective agent includes but is not limited to hydrofluoric acid, 2-iodoxybenzoic acid, sodium periodate, zinc bromide, zirconium tetrachloride or tetrabutylammonium fluoride, preferably tetrabutylammonium fluoride or hydrofluoric acid, more preferably tetrabutylammonium fluoride. The solvent includes but is not limited to acetonitrile, methyl tertiary butyl ether, isopropyl ether, dioxane, toluene, tetrahydrofuran, methyltetrahydrofuran, ethylene glycol diethyl ether, or mixtures of two or more thereof, preferably tetrahydrofuran or toluene, more preferably tetrahydrofuran.
In some representative embodiments, the molar ratio of the compound of formula II to the deprotective agent in step (2) is 1: 1-5, preferably 1: 1-3, more preferably 1: 1-2.
In some representative embodiments, the reaction in step (2) may be carried out at 15-30℃, preferably 25-30℃.
It is noted that the compound with carbon atom marked with *means a mixture of R and S configurations at any ratio, a single enantiomer with R configuration at the carbon atom marked with *, or a single enantiomer with S configuration at the carbon atom marked with *. Wherein, any ratio means the ratio of R configuration to S configuration is, more than 1, equal to 1, less than 1, can be about 50: 50 to 40: 60, or 50: 50 to 60: 40 etc, preferably racemate. At the same time, configuration transformation rarely occurs at the marked *carbon atom.
In the seventh aspect, the invention provides a process for the preparation of ODM-201, comprising: (1) a compound of formula (XI’) is synthesized from hydroxyl-protective reaction of a compound of formula (X’) ; (2) a compound of formula (VIII’) is synthesized from reduction reaction of the compound of formula (XI’) ; (3) a compound of formula (VII’) is synthesized from condensation reaction of the compounds of formula (VIII’) and formula IX; (4) a compound of formula (V’) is synthesized from dehydration reaction of the compound of formula (VII’) ; (5) a compound of formula (VI’) is synthesized from cyclization reaction of the compound of formula (V’) ; (6) a compound of formula (III’) is synthesized from hydrolysis reaction of the compound of formula (VI’) ; (7) a compound of formula (II’) is synthesized from amidation reaction of the compounds of formula (III’) and formula IV; (8) ODM-201 is synthesized from deprotection reaction of the compound of formula (II’) .
Figure PCTCN2017116226-appb-000012
Wherein, R1 and R2 are as defined above.
Wherein, the conditions of each step are also as defined above.
In some representative embodiments, R1 is selected from t-butyldimethylsilyl group; R2 is selected from ethyl group.
In some representative embodiments, the compound of formula (VI’) from step (5) can be directly used in step (6) without separation. The reaction condition is also as defined above.
The invention provides specific compounds as follow:
Figure PCTCN2017116226-appb-000013
The invention also provides the use of above specific compounds in the preparation of  ODM-201.
In the eighth aspect, the invention provides a process for the preparation of the compound of formula Ia, comprising: (1) a compound of formula (XIa) is synthesized from hydroxyl-protective reaction of a compound of formula (Xa) ; (2) a compound of formula (VIIIa) is synthesized from reduction reaction of the compound of formula (XIa) ; (3) a compound of formula (VIIa) is synthesized from condensation reaction of the compounds of formula (VIIIa) and formula IX; (4) a compound of formula (Va) is synthesized from dehydration reaction of the compound of formula (VIIa) ; (5) a compound of formula (VIa) is synthesized from cyclization reaction of the compound of formula (Va) ; (6) a compound of formula (IIIa) is synthesized from hydrolysis reaction of the compound of formula (VIa) ; (7) a compound of formula (IIa) is synthesized from amidation reaction of the compounds of formula (IIIa) and formula IV; (8) the compound of formula Ia is synthesized from deprotection reaction of the compound of formula (IIa) .
Figure PCTCN2017116226-appb-000014
Wherein, R1 and R2 are as defined above.
Wherein, the conditions of each step are also as defined above.
In some representative embodiments, R1 is selected from t-butyldimethylsilyl group; R2 is ethyl group.
In some representative embodiments, the compound of formula (VIa) from step (5) can be directly used in step (6) without separation. The reaction condition is also as defined  above.
The invention provides specific compounds as follow:
Figure PCTCN2017116226-appb-000015
In the ninth aspect, the invention provides a process of the preparation of a compound of formula Ib, comprising: (1) a compound of formula (XIb) is synthesized from hydroxyl-protective reaction of a compound of formula (Xb) ; (2) a compound of formula (VIIIb) is synthesized from reduction reaction of the compound of formula (XIb) ; (3) a compound of formula (VIIb) is synthesized from condensation reaction of the compounds of formula (VIIIb) and formula IX; (4) a compound of formula (Vb) is synthesized from dehydration reaction of the compound of formula (VIIb) ; (5) a compound of formula (VIb) is synthesized from cyclization reaction of the compound of formula (Vb) ; (6) compound of formula (IIIb) is synthesized from hydrolysis reaction of the compound of formula (VIb) ; (7) a compound of formula (IIb) is synthesized from amidation reaction of the compounds of formula (IIIb) and formula IV; (8) the compound of formula Ib is synthesized from deprotection reaction of the compound of formula (IIb) .
Figure PCTCN2017116226-appb-000016
Wherein, R1 and R2 are as defined above.
Wherein, the conditions of each step are also as defined above.
In some representative embodiments, R1 is selected from t-butyldimethylsilyl group; R2 is ethyl group.
In some representative embodiments, the compound of formula (VIb) from step (5) can be directly used in step (6) without separation. The reaction condition is also as defined above.
The invention provides specific compounds as follow:
Figure PCTCN2017116226-appb-000017
Definition
The said hydroxyl protective group in this invention includes but is not limited to the hydroxyl protective groups described in <Protective Groups in Organic Synthesis> (4th edition, John Wiley &Sons: New Jersey) . This literature is incorporated into this invention as reference. In this invention, according to the characters of hydroxyl protective group, a person having ordinary skill in the art could take well known methods to get connect with or rid of the compounds. The hydroxyl protective group described in this invention is selected from pivaloyl group, benzoyl group, acetyl group, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, triisopropylsilyl group, benzyl group, p-methoxybenzyl group, triphenylmethyl group, methoxymethyl group, 2-ethoxyethyl group, 2- (trimethylsilyl) ethoxymethyl group and allyl group.
The molar ratio and ratio of the amount of substance described in this invention are equivalent to each other. In this invention, serial compounds of formula X, such as formula X’, formula Xa and formula Xb are commercially available.
In this invention, the compound of formula IV can be synthesized according the method published in CN201280019463.1
In the invention, the compound of formula IX is commercially available or can be prepared according to methods known in the art.
In the invention, the term of “TBSCl” refers to t-butyldimethylsilyl chloride.
In the invention, the term of “DIBAL-H” refers to diisobutylaluminium hydride.
In the invention, the term of “LIHMDS” refers to lithium bis (trimethylsilyl) amide.
In the invention, the term of “DIPEA” refers to N, N-diisopropylethylamine.
In the invention, the term of “HOBt” refers to1-hydroxybenzotriazole.
In the invention, the term of “EDCI” refers to 1- (3-dimethylaminopropyl) -3-ethylcarbodiimidehydrochloride.
In the invention, the term of “THF” refers to tetrahydrofuran.
In the invention, the term of “dehydrant” refers to the reagent that could help dehydration under heating or catalyst.
In the invention, the term of “condensation reaction” refers to a reaction that one big molecule is formed by covalent bond after interaction between two or more organic molecules or intramolecular reaction within one molecule, and often accompanied by the lost of small molecular (such as water, hydrogen chloride and alcohol etc. ) .
In the invention, the term of “activator of carboxylic acid” refers to the reagent that reacts with carboxylic acid, removes one water molecule, and forms a new compound which  could increase the reactivity of carboxylic group.
In the invention, the term of “condensation agent” refers to a reagent added in the condensation reaction. For example, in an amide reaction, a reagent capable of forming an active intermediate with a carbonyl-containing compound is a condensing agent, and the resulting active intermediate is further reacted with an amine to obtain an amide.
In the invention, the term of “deprotective agent” refers to the reagent that can remove the hydroxyl protective agent, amino protective agent and the like under heating or catalyst.
In the invention, in some representative examples, the chiral compound is in enantiomeric excess. The term of “enantiomeric excess” is the content of a chiral isomer is equal or over about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, about 99.9%or about 99.99%.
In the invention, the graphic representation of racemates, ambiscalemic and scalemic or enantiomerically pure compounds are derived from Maehr, J. Chem. Ed. 1985, 62: 114-120. Unless otherwise specified, the absolute configuration of a stereocenter is indicated by wedged bonds and dashed bonds. When the compounds described herein contain olefinic double bonds or other geometric asymmetric centers, they include the E, Z geometric isomers unless otherwise specified. At the same time, all the tautomeric forms are included in this invention.
In this invention, compounds can have specific geometrical or steric isomers. The invention assumes all these compounds, including cis-and trans-isomers, (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereoisomers, (D) -isomers, (L) -isomers and racemic mixtures or other mixtures thereof. For example, mixtures with stereomeric or diastereomeric excess are both belonging to the range of this invention. Alkyl substituent and the like may contain other asymmetric carbon atoms. All these isomers or their mixtures are belonging to the range of this invention.
In this invention, the reaction is optionally carried out in a solvent. All the solvents are commercially available and can be used without any further purification. Normally, the reaction is conducted under inert nitrogen and in anhydrous solvents.
The compounds are named by a person or software
Figure PCTCN2017116226-appb-000018
Commercially available compounds use the inventory from suppliers.
In this invention, data of proton magnetic resonance is recorded in BRUKER AV-400 (400MHz) spectrometer, and the chemical shift is represented in the low field of  tetramethylsilane (ppm) ; mass spectrum is determined by Q-Tofmicro YA019. Mass spectroscopy is equipped with an electrospray ionization source (ESI) under positive or negative models.
In this invention, the term of “room temperature” refers to 25-30℃.
In this invention, the reaction time unit of “h” refers to hour (s) .
This invention provides a preparation method of a compound of formula I, which has the advantages of easily obtainable starting material, high atomic utilization rate, mild reaction condition, easy post-treatment. In addition, single isomers of formula Ia and formula Ib and ODM-201 can be synthesized directionally by controlling the stereochemistry of starting material, i.e., the compound of XI, with the advantages of simple and controllable process and suitability for industrial production.
EXAMPLES
The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention in any way. The solvents, reagents and raw materials and the like are chemically or analytically pure products and available from commercial sources.
Example 1: methyl (R) -3- ( (tert-butyldimethylsilyl) oxy) butanoate
Figure PCTCN2017116226-appb-000019
To a 500mL three-necked flask, methyl (R) -3-hydroxybutanoate (Xa) (20g, 0.17mol) and imidazole (23g, 0.34mol) were added into anhydrous dichloromethane (350 mL) . Nitrogen was used to replace the air in the flask three times. Tert-butyldimethylsilyl chloride (TBSCl, 30.5g, 0.2mol) was added slowly to this suspension at 0℃. After this addition, the reaction mixture was stirred for 3h at room temperature. TLC showed the completion of the reaction. Then, the reaction mixture was poured into ice water (300mL) to quench. The organic layer was washed with water (three times) and brine (three times) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to dryness to obtain the title compound. Yield 38g (96%) .
Example 2: (R) -3- ( (tert-butyldimethylsilyl) oxy) butanal
Figure PCTCN2017116226-appb-000020
To a 500mL three-necked flask, methyl (R) -3- ( (tert-butyldimethylsilyl) oxy) butanoate (15g, 64mmol) was added into anhydrous dichloromethane (375mL) . Nitrogen was used to replace the air in the flask three times. DIBAL-H (67.7mL, 1.0mol/L in hexane, 67mmol) was added slowly to the solution at -78℃. After this addition, the reaction mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the addition of methanol (15mL) . The reaction mixture was poured onto a saturated aqueous solution of sodium potassium tartrate (200mL) and extracted with ether (3x300 mL) . The combined organic layer was washed with water (three times) and brine (three times) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound. Yield 12 g (92%) .
Example 3: ethyl (5R) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate
Figure PCTCN2017116226-appb-000021
To a 500mL three-necked flask, (R) -3- ( (tert-butyldimethylsilyl) oxy) butanal (VIIIa, 10g, 49mmol) and ethyl diazoacetate (8.9g, 78 mmol) were added into anhydrous THF (300mL) . Nitrogen was used to replace the air in the flask three times. LIHMDS (74mL, 1.0mol/L in THF, 74mmol) was added slowly to the solution at -78℃. After this addition, the reaction mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the addition of saturated aqueous solution of ammonium chloride (100mL) and stirred until the temperature increased to room temperature. The solution was extracted with ethyl acetate (3x300mL) . The combined organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to obtain the title compound. Yield 13g (83.3%) .
ESI-MS (m/z) : 317 [M+H] +.
1H-NMR (400 MHz, CDCl3-d) : δ=4.99 -4.73 (m, 1H) , 4.27 -4.07 (m, 3H) , 3.58 (d, 1H) , 1.81 (m, 2H) , 1.30 -1.20 (m, 6H) , 0.90 (s, 9H) , 0.10 (d, J=3.9Hz, 6H) .
Example 4: ethyl (5R) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate
Figure PCTCN2017116226-appb-000022
To a 100mL three-necked flask, ethyl (5R) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate (5g, 15.75mmol) and triethylamine (4.0g, 40mmol) were added into anhydrous dichloromethane (60mL) . Trifluoroacetic anhydride (6.6g, 31.55mmol) was added dropwise at -10℃. After this addition, the temperature was increased slowly to room temperature, and the reaction mixture was stirred for 2h at room temperature. TLC showed the completion of the reaction. Then the reaction was quenched by adding ice water (50mL) and extracted with ether (50mL) . The organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to dryness to obtain the title compound. Yield 3.8g (80%) .
ESI-MS (m/z) : 299 [M+H] +.
1H-NMR (400 MHz, CHCl3-d3) : δ=5.96 (dd, J=15.8, 1.4z, 1H) , 5.35 (d, J=15.8, 1H) , 4.54 -4.36 (m, 1H) , 4.26 (q, J=7.2Hz, 2H) , 1.30 (t, J=7.1Hz, 3H) , 1.24 (d, J=6.3Hz, 3H) , 0.90 (s, 9H) , 0.07 (d, J=3.9Hz, 6H) .
Example 5: (5R) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid
Figure PCTCN2017116226-appb-000023
To a 100mL three-necked flask, ethyl (5R) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate (3.5g, 11.74mmol) and n-octane (25mL) were added at room temperature. The reaction mixture was heated to reflux for 1h. TLC showed the completion of the reaction. Then THF (45mL) and 10%aqueous sodium hydroxide (0.98g, 24.5mmol) were added at room temperature. After this addition, the reaction mixture was heated to reflux and stirred for 1h.Solvent was evaporated under reduced pressure to dryness at 50℃ and the residue was dissolved in water (30mL) . After treatment with 1N hydrochloric acid until pH≈4, the solution was stirred until the solid was precipitated for 5h, filtered, and dried under vacuum at 50℃ for 5h to obtain the title compound. Yield 2.6g (82%) .
ESI-MS (m/z) : 271 [M+H] +.
1H-NMR (400 MHz, DMSO-d3) : δ=13.17 (br, H) , 6.51 (s, 1H) , 4.93 (q, J=6.4Hz, 1H) , 1.40 (d, J=6.4 Hz, 3H) , 0.85 (s, 9H) , 0.05 (s, 3H) , -0.03 (s, 3H) .
Example 6: 5- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide
Figure PCTCN2017116226-appb-000024
To a 50mL three-necked flask, (5R) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid (2.4g, 8.84mmol) , DIPEA (1.2g, 9.2mmol) , HOBt (1.2g, 8.84mmol) , EDCI (1.68g, 8.84mmol) and (S) -4- (1- (2-aminopropyl) -1H-pyrazol-3-yl) -2-chlorobenzonitrile (compound of formula IV) (2.0 g, 7.68mmol) were added into anhydrous dichloromethane (28mL) at room temperature. The reaction solution was stirred at room temperature for 5h. TLC showed the completion of the reaction. Then solvent was evaporated to dryness and the residue was dissolved in water (50mL) and ethyl acetate (100mL) . The organic layer was washed with water (3x20mL) and brine (3x20mL) and concentrated under reduced pressure to obtain the crude product. Isopropanol (18mL) was added to the concentrate and heated to reflux, then water (3mL) was added. The solution was cooled down to 0℃ and the solidwas precipitated, filtered and dried under vacuum at 50℃ to obtain the title compound. Yield 3.2g (82%) .
ESI-MS (m/z) : 535 [M+Na] +.
1H-NMR (400 MHz, DMSO-d3) : δ=13.10 (s, 1H) , 8.19 (s, 1H) , 8.07 (s, 1H) , 7.96 (s, 2H) , 7.81 (s, 1H) , 6.92 (s, 1H) , 6.41 (s, 1H) , 4.98 (t, J=6.2Hz, 1H) , 4.36 (m, 3H) , 1.41 (d, J=6.2Hz, 3H) , 1.11 (d, J=6.2Hz, 3H) , 0.83 (s, 9H) , 0.03 (s, 3H) , -0.05 (s, 3H) .
Example 7: N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -5- ( (R) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide (compound of formula Ia)
Figure PCTCN2017116226-appb-000025
To a 100mL three-necked flask, 5- ( (R) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide (3.0g, 5.84mmol) was added into THF (48mL) at room temperature. Tetrabutylammonium fluoride (11.68mL, 1.0mol/L in THF, 11.68mmol) was added dropwise at 0℃. The reaction solution was stirred for 5h at 25 ℃. TLC showed the completion of the reaction. Then the reaction was quenched by water (50mL) and extracted with ethyl acetate (40mL) . The organic layer was washed with water (3x20mL) and brine (3x20mL) and concentrated under reduced pressure to obtain the title compound (compound of formula Ia) . Yield 2.1g (91%) ; chemical purity: 99.96%; optical purity: 99.2%.
ESI-MS (m/z) : 421 [M+Na] +.
1H-NMR (400 MHz, DMSO-d3) : δ=13.15 (s, 1H) , 8.24 (s, 1H) , 8.08 (s, 1H) , 7.98 (s, 2H) , 7.82 (s, 1H) , 6.93 (s, 1H) , 6.43 (s, 1H) , 5.45 (s, 1H) , 4.78 (s, 1H) , 4.32 (m, 3H) , 1.37 (d, J=6.4Hz, 3H) , 1.11 (d, J=6.3Hz, 3H) .
Example 8: methyl (S) -3- ( (tert-butyldimethylsilyl) oxy) butanoate
Figure PCTCN2017116226-appb-000026
To a 500mL three-necked flask, methyl (S) -3-hydroxybutanoate (compound of formula Xb) (20g, 0.17mol) and imidazole (23g, 0.34mol) were added into anhydrous dichloromethane (350 mL) . Nitrogen was used to replace the air in the flask three times. Tert-butyldimethylsilyl chloride (TBSCl, 30.5g, 0.2mol) was added slowly to this suspension at 0℃. After this addition, the reaction mixture was stirred for 3h at room temperature. TLC showed the completion of the reaction. Then the reaction mixture was poured into ice water (300mL) to quench. The organic layer was washed with water (three times) and brine (three times) , dried over sodium sulfate, filtered and concentrated under reduced pressure to dryness to obtain the title compound. Yield 37.5g (95.4%) .
Example 9: (S) -3- ( (tert-butyldimethylsilyl) oxy) butanal
Figure PCTCN2017116226-appb-000027
To a 1L three-necked flask, methyl (S) -3- ( (tert-butyldimethylsilyl) oxy) butanoate (20g,  86.2mmol) was added into anhydrous dichloromethane (500mL) . Nitrogen was used to replace the air in the flask three times. DIBAL-H (90.5mL, 1mol/L in hexane, 90.5mmol) was added slowly to the solutionat -78℃. The mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the addition of methanol (25mL) . The reaction mixture was poured onto a saturated aqueous solution of sodium potassium tartrate (300mL) and extracted with ether (300mL×3) . The combined organic layer was washed with water (three times) and brine (three times) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound. Yield 16.6 g (95.4%) .
Example 10: ethyl (5S) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate
Figure PCTCN2017116226-appb-000028
To a 500mLthree-necked flask, (S) -3- ( (tert-butyldimethylsilyl) oxy) butanal (15g, 74.1mmol) , ethyl diazoacetate (13.5g, 118.6mmol) were added into anhydrous THF (350mL) . Nitrogen was used to replace the air in the flask three times. LIHMDS (111mL, 1.0mol/L in THF, 111.1mmol) was added slowly to the solution at -78℃. The mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the saturated aqueous solution of ammonium chloride (200mL) and stirred until the temperature increased to room temperature. The solution was extracted with ethyl acetate (300mL×3) . The combined organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to obtain the title compound. Yield 19.2g (82%) .
ESI-MS (m/z) : 317 [M+H] +.
Example 11: ethyl (5S) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate
Figure PCTCN2017116226-appb-000029
To a 500mL three-necked flask, ethyl (5S) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate (16g, 50.55mmol) and triethylamine (25.25g, 250mmol) were added into anhydrous dichloromethane (300mL) . Trifluoroacetic anhydride (21.23g, 101.11mmol) was  added dropwise at -10℃. After this addition, the temperature was increased slowly to room temperature, and the reaction mixture was stirred for 5h at room temperature. TLC showed the completion of the reaction. Then the reaction was quenched by adding ice water (100mL) and extracted with ether (50mL) . The organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to obtain the title compound. Yield 13.2g (88.0%) .
ESI-MS (m/z) : 299 [M+H] +.
Example 12: (5S) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid
Figure PCTCN2017116226-appb-000030
To a 250mLthree-necked flask, ethyl (5S) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate (10.0g, 33.50mmol) and n-octane (66mL) were added at room temperature. The reaction mixture was heated to reflux for 1h. TLC showed the completion of the reaction. Then THF (100mL) and 10%aqueous sodium hydroxide (2.68g, 67.0mmol) were added at room temperature. After this addition, the reaction mixture was heated to reflux and stirred for 4h.Solvent was evaporated to dryness at 50℃ and the residue was dissolved in water (30mL) . After treatment with 1N hydrochloric acid until pH≈4, the solution was stirred until the solid was precipitated for 5h, filtered, and dried under vacuum at 50℃ for 5h to obtain the title compound. Yield 6.8g (75.5%) .
ESI-MS (m/z) : 271 [M+H] +.
Example 13: 5- ( (S) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide
Figure PCTCN2017116226-appb-000031
To a 50mL three-necked flask, (5S) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid (3.5g, 12.94mmol) , DIPEA (1.74g, 13.5mmol) , HOBt (1.75g,  12.94mmol) , EDCI (2.48g, 12.94mmol) and (S) -4- (1- (2-aminopropyl) -1H-pyrazol-3-yl) -2-chlorobenzonitrile (compound of formula IV) (2.9g, 11.25mmol) were added into anhydrous dichloromethane (39mL) at room temperature. The reaction solution was stirred at room temperature for 5h. TLC showed the completion of the reaction. Then solvent was evaporated to dryness and the residue was dissolved in water (50mL) and ethyl acetate (120mL) . The organic layer was washed with water (3x50mL) and brine (3x50mL) and concentrated under reduced pressure. Isopropanol (30mL) was added into the concentrate and heated to reflux, then water (5mL) was added. The solution was cooled down to 0℃and the solid was precipitated, filtered and dried under vacuum at 50℃ to obtain the title compound. Yield 4.5g (78.6%) .
ESI-MS (m/z) : 535 [M+Na] +.
Example 14: N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- ( (S) -1-hydroxyethyl) -1H-pyrazole-3-carboxamide (compound of formula Ib)
Figure PCTCN2017116226-appb-000032
To a 100mL three-necked flask, 5- ( (S) -1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide (4.0g, 7.79mmol) was added into THF (54mL) at room temperature. Tetrabutylammonium fluoride (15.59mL, 1.0mol/L in THF, 15.59mmol) was added dropwise at 0℃. The reaction solution was stirred for 6h at 25 ℃. TLC showed the completion of the reaction. Then the reaction was quenched by water (60mL) and extracted with ethyl acetate (50mL) . The organic layer was washed with water (30mL×3) and brine (30mL×3) and concentrated under reduced pressure to obtain the title compound (compound of formula Ib) . Yield 2.8g (90%) ; chemical purity: 99.86%; optical purity: 99.54%.
ESI-MS (m/z) : 421 [M+Na] +.
1H-NMR (400 MHz, DMSO-d3) : δ=13.04 (s, 1H) , 8.19 (s, 1H) , 8.09 (s, 1H) , 8.00 (s, 2H) , 7.82 (s, 1H) , 6.94 (s, 1H) , 6.41 (s, 1H) , 5.41 (s, 1H) , 4.82 (s, 1H) , 4.39 (m, 3H) , 1.39 (d, J=6.4Hz, 3H) , 1.12 (d, J=6.3Hz, 3H) .
Example 15: methyl-3- ( (tert-butyldimethylsilyl) oxy) butanoate
Figure PCTCN2017116226-appb-000033
To a 500mL three-necked flask, methyl3-hydroxybutanoate (20g, 0.17mol) and imidazole (23g, 0.34mol) were added into anhydrous dichloromethane (350mL) . Nitrogen was used to replace the air in the flask three times. Tert-butyldimethylsilyl chloride (TBSCl, 30.5g, 0.2mol) was added slowly to this suspension at 0℃. After this addition, the reaction mixture was stirred for 3h at room temperature. TLC showed the completion of the reaction. Then the reaction mixture was poured into ice water (300mL) to quench. The organic layer was washed with water (three times) and brine (three times) , dried over sodium sulfate, filtered and concentrated under reduced pressure to dryness to obtain the title compound. Yield 37.5g (95.4%) .
Example 16: 3- ( (tert-butyldimethylsilyl) oxy) butanal
Figure PCTCN2017116226-appb-000034
To a 1L three-necked flask, methyl3- ( (tert-butyldimethylsilyl) oxy) butanoate (20g, 86.2mmol) was added into anhydrous dichloromethane (500mL) . Nitrogen was used to replace the air in the flask three times. DIBAL-H (90.5mL, 1mol/L in hexane, 90.5mmol) was added slowly to this solution at -78℃. The mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the addition of methanol (25mL) . The reaction mixture was poured onto a saturated aqueous solution of sodium potassium tartrate (300mL) and extracted with ether (300mL×3) . The combined organic layer was washed with water (three times) and brine (three times) , dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the title compound. Yield 15.6 g (89.6%) .
Example 17: ethyl-5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate
Figure PCTCN2017116226-appb-000035
To a 500mL three-necked flask, 3- ( (tert-butyldimethylsilyl) oxy) butanal (15g,  74.1mmol) , ethyl diazoacetate (13.5g, 118.6mmol) were added into anhydrous THF (350mL) . Nitrogen was used to replace the air in the flask three times. LIHMDS (111mL, 1.0mol/L in THF, 111.1mmol) was added slowly to this solution at -78℃. The mixture was stirred at -78℃ for 1h. TLC showed the completion of the reaction. Then the reaction was quenched by the saturated aqueous solution of ammonium chloride (200mL) and stirred until the temperature increased to room temperature. The solution was extracted with ethyl acetate (300mL×3) . The combined organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to obtain the title compound. Yield 18.9g (80.7%) .
ESI-MS (m/z) : 317 [M+H] +.
Example 18: ethyl-5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate
Figure PCTCN2017116226-appb-000036
To a 500mL three-necked flask, ethyl5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-3-hydroxy-hexanoate (16g, 50.55mmol) and triethylamine (25.25g, 250mmol) were added into anhydrous dichloromethane (300mL) . Trifluoroacetic anhydride (21.23g, 101.11mmol) was added dropwise at -10℃. After this addition, the temperature was increased slowly to room temperature, and the reaction mixture was stirred for 5h at room temperature. TLC showed the completion of the reaction. Then the reaction was quenched by adding ice water (100mL) and extracted with ether (50mL) . The organic layer was washed with brine (three times) , dried over anhydrous sodium sulfate, filtered with silica gel and concentrated under reduced pressure to obtain the title compound. Yield 12.8g (85.3%) .
ESI-MS (m/z) : 299 [M+H] +.
Example 19: 5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid
Figure PCTCN2017116226-appb-000037
To a 250mL three-necked flask, ethyl 5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate (8.0g, 26.84mmol) and n-octane (53mL) were added at room temperature. The reaction mixture was heated to reflux for 1h. TLC showed the completion of the reaction. Then THF (100mL) and 10%aqueous sodium hydroxide (2.15g, 53.69mmol) were added at room  temperature. After this addition, the reaction mixture was heated to reflux and stirred for 4h. Solvent was evaporated to dryness at 50℃ and the residue was dissolved in water (30mL) . After treatment with 1Nhydrochloric acid until pH≈4, the solution was stirred until the solid was precipitated for 5h, filtered, and dried under vacuum at 50℃ for 5h to obtain the title compound. Yield 5.5g (75.96%) .
ESI-MS (m/z) : 271 [M+H] +.
Example 20: 5- (-1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide
Figure PCTCN2017116226-appb-000038
To a 50mL three-necked flask, 5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid (3.5g, 12.94mmol) , DIPEA (1.74g, 13.5mmol) , HOBt (1.75g, 12.94mmol) , EDCI (2.48g, 12.94mmol) and (S) -4- (1- (2-aminopropyl) -1H-pyrazol-3-yl) -2-chlorobenzonitrile (compound of formula IV) (2.9g, 11.25mmol) were added into anhydrous dichloromethane (39mL) at room temperature. The reaction solution was stirred at room temperature for 5h. TLC showed the completion of the reaction. Then solvent was evaporated to dryness and the residue was dissolved in water (50 mL) and ethyl acetate (120mL) . The organic layer was washed with water (3x50mL) and brine (3x50mL) and concentrated under reduced pressure. The isopropanol (30mL) was added to the concentrate and heated to reflux, then water (5mL) was added. The solution was cooled down to 0℃and the solidwas precipitated, filtered and dried under vacuum at 50℃ to obtain the title compound. Yield 4.8g (83.9%) .
ESI-MS (m/z) : 535 [M+Na] +.
Example 21: N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) -propan-2-yl) -5- (1-hydroxyethyl) -1H-pyrazole-3-carboxamide (ODM-201)
Figure PCTCN2017116226-appb-000039
To a 100mL three-necked flask, 5- (-1- ( (tert-butyldimethylsilyl) oxy) ethyl) -N- ( (S) -1- (3- (3-chloro-4-cyanophenyl) -1H-pyrazol-1-yl) propan-2-yl) -1H-pyrazole-3-carboxamide (4.0g, 7.79mmol) was added into THF (54mL) at room temperature. Tetrabutylammonium fluoride (15.59mL, 1.0mol/L in THF, 15.59mmol) was added dropwise at 0℃. The reaction solution was stirred for 6h. TLC showed the completion of the reaction. Then the reaction was quenched by water (60mL) and extracted with ethyl acetate (50mL) . The organic layer was washed with water (30mL×3) and brine (30mL×3) and concentrated under reduced pressure to obtain the title compound (ODM-201) . Yield 2.88g (92.9%) ; chemical purity: 99.6%.
ESI-MS (m/z) : 421 [M+Na] +.
1H-NMR (400 MHz, DMSO-d3) : δ=13.03 (s, 1H) , 8.19 (d, J=8.5Hz, 1H) , 8.07 (s, 1H) , 7.97 (s, 2H) , 7.81 (d, J=2.3Hz, 1H) , 6.93 (s, 1H) , 6.40 (s, 1H) , 5.40 (d, J=5.0Hz, 1H) , 4.85-4.67 (s, 1H) , 4.33 (m, 3H) , 1.38 (d, J=6.5Hz, 3H) , 1.11 (d, J=6.5Hz, 3H) .
Example 22: ethyl (5R) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylate
Figure PCTCN2017116226-appb-000040
To a 100mL three-necked flask, ethyl (5R) -5- ( (tert-butyldimethylsilyl) oxy) -2-diazo-hex-3-enoate (3.5g, 11.74mmol) and n-octane (25mL) were added at room temperature. The reaction mixture was heated to reflux for 1h. TLC showed the completion of the reaction. The reaction solution was concentrated under reduced pressure at 80℃ to obtain oily title compound. Yield 3.5g (100%) .
Example 23: (5R) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylic acid
Figure PCTCN2017116226-appb-000041
To a 100mL three-necked flask, ethyl (5R) -5- (1- ( (tert-butyldimethylsilyl) oxy) ethyl) -1H-pyrazole-3-carboxylate (3.5g, 11.74mmol) , THF (45mL) and 10%aqueous sodium hydroxide (0.98g, 24.5mmol) were added at room temperature. After this addition, the reaction mixture was heated to reflux and stirred for 1h. Solvent was evaporated under reduced pressure to dryness at 50℃ and the residue was dissolved in water (30mL) . After treatment with 1N hydrochloric acid until pH≈4, the solution was stirred until the solid was precipitated for 5h, filtered, and dried under vacuum at 50℃ for 5h to obtain the title compound. Yield 2.6g (82%) .
ESI-MS (m/z) : 271 [M+H] +.
1HNMR (400 MHz, DMSO -d3) : δ = 13.17 (br, H) , 6.51 (s, 1H) , 4.93 (q, J = 6.4 Hz, 1H) , 1.40 (d, J = 6.4 Hz, 3H) , 0.85 (s, 9H) , 0.05 (s, 3H) , -0.03 (s, 3H) .

Claims (12)

  1. A process for the preparation of a compound of formula VI, comprising conducting cyclization reaction of a compound of formula V to obtain the compound of formula VI,
    Figure PCTCN2017116226-appb-100001
    wherein, R1 is hydroxyl protective group; R2 is C1-6 alkyl group.
  2. The process for the preparation of the compound of formula VI according to claim 1, wherein, the hydroxyl protective group (R1) is selected from pivaloyl group, benzoyl group, acetyl group, trimethylsilyl group, triethylsilyl group, t-butyldimethylsilyl group, t-butyldiphenylsilyl group, triisopropylsilyl group, benzyl group, p-methoxybenzyl group, triphenylmethyl group, methoxymethyl group, 2-ethoxyethyl group, 2-(trimethylsilyl) ethoxymethyl group and allyl group.
  3. The process for the preparation of the compound of formula VI according to claim 1, wherein, R2 is selected from methyl, ethyl, n-propyl group, isopropyl group, n-butyl group, isobutyl group, s-butyl group and t-butyl group.
  4. The process for the preparation of the compound of formula VI according to claim 1, wherein, the cyclization reaction is carried out in a solvent selected from tetrachloromethane, chloroform, dichloromethane, n-hexane, n-heptane, n-octane, isooctane, or mixtures of two or more thereof.
  5. A process for the preparation of a compound of formula III, comprising conducting hydrolysis reaction of a compound of formula VI to obtain the compound of formula III
    Figure PCTCN2017116226-appb-100002
    wherein, R1 and R2 are as defined in claim 1.
  6. A process for the preparation of a compound of formula I, comprising the following steps: (1) conducting amidation reaction of a compound of formula III and a compound of formula IV to obtain a compound of formula II; and (2) conducting deprotection reaction of the compound of formula II to obtain the compound of formula I,
    Figure PCTCN2017116226-appb-100003
    wherein, R1 and R2 are as defined in claim 1.
  7. A process for the preparation of a compound of formula (V) , comprising the following steps: (1) conducting condensation reaction of a compound of formula VIII and a compound of formula IX to obtain a compound of formula VII; and (2) conducting dehydration reaction of a compound of formula VII to obtain a compound of formula V,
    Figure PCTCN2017116226-appb-100004
    wherein, R1 and R2 are as defined in claim 1.
  8. A process for the preparation of a compound of formula VIII, comprising the following steps: (1) conducting hydroxyl-protection reaction of a compound of formula X to obtain a compound of formula XI; and (2) conducting reduction reaction of a compound of formula XI to obtain a compound of formula VIII,
    Figure PCTCN2017116226-appb-100005
    wherein, R1is as defined in claim 1.
  9. A compound selected from the group consisting of:
    Figure PCTCN2017116226-appb-100006
  10. Use of the compound according to claim 9 in a process for the preparation of ODM-201.
  11. A process for the preparation of ODM201,
    Figure PCTCN2017116226-appb-100007
    comprising the following steps:
    a) conducting cyclization reaction of a compound of formula V’ to obtain a compound of formula VI’ ,
    Figure PCTCN2017116226-appb-100008
    wherein, R1 is hydroxyl protective group; R2 is C1-6 alkyl group,
    b) the thus obtained compound of formula VI’ is hydrolyzed to obtain a compound of  formula III’
    Figure PCTCN2017116226-appb-100009
    c) the compound of formula III’ is reacted with a compound of formula IV to obtain a compound of formula II’
    Figure PCTCN2017116226-appb-100010
    and
    d) the protected compound of formula II’ is deprotected to obtain ODM201
    Figure PCTCN2017116226-appb-100011
  12. A process for the preparation of a compound of formula I,
    Figure PCTCN2017116226-appb-100012
    comprising the following steps:
    a) conducting cyclization reaction of a compound of formula V to obtain a compound of formula VI,
    Figure PCTCN2017116226-appb-100013
    wherein, R1 is hydroxyl protective group; R2 is C1-6 alkyl group,
    b) the thus obtained compound of formula VI is hydrolyzed to obtain a compound of formula III,
    Figure PCTCN2017116226-appb-100014
    c) the compound of formula III is reacted with a compound of formula IV to obtain a compound of formula II,
    Figure PCTCN2017116226-appb-100015
    and
    d) the protected compound of formula II is deprotected to obtain the compound of formula I.
    Figure PCTCN2017116226-appb-100016
PCT/CN2017/116226 2016-12-15 2017-12-14 Process for preparation of novel androgen receptor antagonist Ceased WO2018108130A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611157085.X 2016-12-15
CN201611157085.XA CN108218908A (en) 2016-12-15 2016-12-15 A kind of preparation method of novel androgen receptor antagonists

Publications (1)

Publication Number Publication Date
WO2018108130A1 true WO2018108130A1 (en) 2018-06-21

Family

ID=62558012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/116226 Ceased WO2018108130A1 (en) 2016-12-15 2017-12-14 Process for preparation of novel androgen receptor antagonist

Country Status (2)

Country Link
CN (1) CN108218908A (en)
WO (1) WO2018108130A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2843187C1 (en) * 2020-05-11 2025-07-08 Орион Корпорейшн Method of producing androgen receptor antagonists and intermediate compounds thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111116476A (en) * 2019-12-27 2020-05-08 武汉九州钰民医药科技有限公司 Method for preparing antitumor drug doramemide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143599A1 (en) * 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
WO2016120530A1 (en) * 2015-01-30 2016-08-04 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143599A1 (en) * 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
WO2016120530A1 (en) * 2015-01-30 2016-08-04 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HE, SHENG ET AL.: "1, 3-Dipolar cycloaddition of diazoacetate compounds to terminal alkyne: promoted by Zn(OTf)2: an efficient way to the preparation of pyrazoles", TETRAHEDRON LETTERS, vol. 50, no. 20, 11 March 2009 (2009-03-11), pages 2443 - 2445, XP026063218 *
PADWA, ALBERT ET AL.: "Reaction of Carbonyl Compounds with Ethyl Lithiodiazoacetate. Studies Dealing with the Rhodium (It) -Catalyzed Behavior of the Resulting Adducts", J.ORG.CHEM., vol. 55, no. 13, 31 December 1990 (1990-12-31) *
PAN, TINGTING ET AL.: "Chemical synthesis of the ODM-201's Diastereomers through an Efficient Intramolecular 1, 3-Dipolar Cycloaddition", CHEM.PHARM.BULL., vol. 65, no. 6, 5 April 2017 (2017-04-05), pages 582 - 585, XP055509635 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2843187C1 (en) * 2020-05-11 2025-07-08 Орион Корпорейшн Method of producing androgen receptor antagonists and intermediate compounds thereof

Also Published As

Publication number Publication date
CN108218908A (en) 2018-06-29

Similar Documents

Publication Publication Date Title
HU225294B1 (en) Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof
CN103703014A (en) Method for producing estetrol intermediate
CN104230978B (en) Ezetimibe prepare intermediate and preparation method thereof
CN102630226A (en) Entecavir synthesis method and intermediate compound thereof
WO2013135165A1 (en) Synthetic intermediate of entecavir and method for preparing same
JP2013170151A (en) Direct method for producing indole-3-triflone and indole triflone derivative
WO2011004389A2 (en) An improved process for the preparation of elvitegravir
JP2007538041A (en) Method for producing diphenylazetidinone derivative
CN113387829A (en) Preparation method of shakubiqu
Monleón et al. Radical cyclisation of epoxynitrile-2-azetidinones mediated by Cp2TiCl
WO2018108130A1 (en) Process for preparation of novel androgen receptor antagonist
MXPA02001396A (en) Process for the preparation of a paclitaxel c-4 methyl carbonate analog.
CN102827030B (en) Preparation method of (3R,5R)-3,5-dihydroxy-6-methyl cyan-caproate
JP5960130B2 (en) Preparation of tesetaxel and related compounds and corresponding synthetic intermediates
CN119504830A (en) A key intermediate of monepantel and its splitting method
CA2922210A1 (en) Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib
CN101277966A (en) Method for synthesizing HMG-CoA reductase inhibitors
WO2014094511A1 (en) Intermediates for synthesizing treprostinil and preparation method thereof as well as the preparation method of treprostinil thereby
CN106496263B (en) Process for producing hexahydrofurofuranol derivative, intermediate therefor, and process for producing the intermediate
US7550608B2 (en) Processes for the preparation of docetaxel
WO2014108011A1 (en) Entecavir intermediates and preparation method thereof
CN103159705B (en) Preparation method for cabazitaxel intermediate
CN102020658B (en) 2-Chloro-6,8-dihydro-5H-imidazol[2,1-c]-[1,4]oxazine and its preparation method
CN110092753B (en) A kind of preparation method of synthesizing 3-azabicyclo[4.1.0]heptane-2-carboxylic acid and its hydrochloride
JP3655939B2 (en) Novel process for the preparation of 13-alkyl milbemycin intermediates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17881083

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17881083

Country of ref document: EP

Kind code of ref document: A1